This multicenter randomized trial sponsored by UNICANCER evaluates the efficacy of a combination of triptorelin and flutamide with external-beam radiation therapy versus radiation therapy alone in patients with localized prostate cancer of intermediate prognosis. The trial's completion in October 2015 positions it to potentially influence treatment protocols and market dynamics for prostate cancer therapies. The results may enhance the competitive positioning of triptorelin and flutamide in the oncology market, particularly against existing androgen deprivation therapies. Given the increasing prevalence of prostate cancer, successful outcomes could lead to expanded market opportunities and necessitate diligence in assessing the competitive landscape, including other hormonal therapies and radiation modalities.